APA (7th ed.) Citation

Sundén-Cullberg, J., Chen, P., Häbel, H., Skorup, P., Janols, H., Rasmuson, J., . . . Vesterbacka, J. (2023). Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial. PLoS ONE, 18(12), 1. https://doi.org/10.1371/journal.pone.0295838

Chicago Style (17th ed.) Citation

Sundén-Cullberg, Jonas, et al. "Anakinra or Tocilizumab in Patients Admitted to Hospital with Severe Covid-19 at High Risk of Deterioration (IMMCoVA): A Randomized, Controlled, Open-label Trial." PLoS ONE 18, no. 12 (2023): 1. https://doi.org/10.1371/journal.pone.0295838.

MLA (9th ed.) Citation

Sundén-Cullberg, Jonas, et al. "Anakinra or Tocilizumab in Patients Admitted to Hospital with Severe Covid-19 at High Risk of Deterioration (IMMCoVA): A Randomized, Controlled, Open-label Trial." PLoS ONE, vol. 18, no. 12, 2023, p. 1, https://doi.org/10.1371/journal.pone.0295838.